Text Size
Trial record 9 of 208 for:    Open Studies | "Bipolar Disorder"
Previous Study | Return to List | Next Study

Observation Study of the Clinical Management of Bipolar Disorder

This study is currently recruiting participants.
Verified March 2013 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01770704
First received: January 16, 2013
Last updated: March 4, 2013
Last verified: March 2013
History of Changes
  Purpose

The objective of the ambispective cohort study is to describe clinical management and clinical outcomes related to bipolar disorder in China, and establish the factors associated with different management patterns and clinical outcomes, provide psychiatrists with reliable and up-to-date information on the disease.


Condition
Bipolar Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Chinese Observation Study of the Clinical Management of Bipolar Disorder

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of episodes (depression, mania, hypomania or mixed). [ Time Frame: Up to 21 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Treatments received for Bipolar Disorder: medication time. [ Time Frame: Up to 21 months ] [ Designated as safety issue: No ]
  • Treatments received for Bipolar Disorder: medication classes. [ Time Frame: Up to 21 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: February 2012
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients diagnosed with bipolar disorder I or II

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients diagnosed with bipolar disorder I or II with at least one mood event during the 3 and 12 months prior to the beginning of the study.

Criteria

Inclusion Criteria:

  • Provision of subject informed consent.
  • Diagnosis of Bipolar Disorder I or II (DSM-IV TR) in any phase of the disorder.
  • Patients who had at least one mood event( depression, mania, hypomania or mixed) according to DSM-IV TR definition during the 3 and 12 months prior to the beginning of the study.

Exclusion Criteria:

  • Inability to complete Patient Reported Outcomes (PROs) questionnaires.
  • Participation in an interventional clinical study in last 12 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01770704

Contacts
Contact: AstraZeneca Clinical Study Information 862160301308 jingjing.jiang@astrazeneca.com

Locations
China, Beijing
Research Site Recruiting
Beijing, Beijing, China
China, Guangdong
Research Site Not yet recruiting
Shenzhen, Guangdong, China
China, Shanghai
Reserach Site Recruiting
Shanghai, Shanghai, China
China, Shanxi
Research Site Not yet recruiting
Xi'an, Shanxi, China
China, Yunnan
Research SIte Not yet recruiting
Kunming, Yunnan, China
China, Zhejiang
Research Site Not yet recruiting
Hangzhou, Zhejiang, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Yu Xin Beijing No.6 Hospital
Principal Investigator: Wang Gang Capital Medical University
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01770704     History of Changes
Other Study ID Numbers: NIS-NCN-XXX-2012/1
Study First Received: January 16, 2013
Last Updated: March 4, 2013
Health Authority: China: Ethics Committee

Keywords provided by AstraZeneca:
Bipolar disorder
Clinical management
Clinical outcomes

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2013